Nomogram useful for survival prognostication in sarcoma patients
Sarculator, an online validated nomogram, is a good predictor of actual overall survival (aOS) in patients with resected, primary extremity sarcomas, according to a study.
The Sarculator algorithm uses patient age, tumor size (cm), grade (1-3), and histology to calculate predicted overall survival (pOS). Researchers compared pOS of 9738 patients with aOS. Harrell’s C-index was calculated to determine the discriminatory ability of Sarculator (0.7 = good, 0.8 = strong, 1.0 = perfect model),
At 5-years, the pOS was 73.7% and the aOS was 68.9%. The C-index for the entire cohort was 0.726. For stage I, stage II, and stage III, the C-index was 0.730, 0.708, and 0.679, respectively. C-indices were highest for leiomyosarcoma (0.745), myxofibrosarcoma (0.722), and other histologies (0.721), and in patients < 50 years (C-index 0.722), of other/unknown race (C-index 0.781), with private insurance (C-index 0.715), treated at a center other than a community cancer programs (C-index > 0.7), and with no comorbidities (C-index 0.716).
Voss RK, Callegaro D, Chiang YJ, et al. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Ann Surg Oncol. 2022;doi: 10.1245/s10434-022-11442-2. Epub ahead of print. PMID: 35224688.